Status:
COMPLETED
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Lead Sponsor:
Pfizer
Collaborating Sponsors:
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Analysis Group, Inc.
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.
Detailed Description
Clear cell mRCC patients who initiated sunitinib as first-line treatment between 2010 and 2018 were identified from the IMDC database. Patients were classified as favorable, intermediate, or poor prog...
Eligibility Criteria
Inclusion
- Diagnosed with mRCC
- Initiated treatment post mRCC diagnosis and received sunitinib as first-line therapy
- Age 18 years or over at the time of mRCC diagnosis
- Actively treated at an IMDC clinical center
Exclusion
- Initiated first line sunitinib treatment before 2010
- Had non-clear cell mRCC
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 2 2018
Estimated Enrollment :
1769 Patients enrolled
Trial Details
Trial ID
NCT04076787
Start Date
September 1 2018
End Date
September 2 2018
Last Update
April 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, P2N4N2